New developments in COVID-19 consortium RECOVER

The RECOVER primary care study (work package 2), SOS-COVID, started in March 2020 and enrolled their first patients in the Netherlands on April 14th. The study aims to generate evidence about milder and/or undiagnosed SARS-CoV-2 infection, as well as to track the impact of the disease when managed outside the hospital. Since March, an additional 260 patients were included in the trial from 4 countries. The social sciences team of work package 2 has also conducted interviews with patients and general practitioners in 6 countries to generate understanding of their perspectives in receiving and providing primary care during the pandemic.

The MERMAIDS-ARI 2.0 study, an expansion of the re-activated MERMAIDS ARI study in the PREPARE consortium and work package 3 (WP3) of RECOVER, has enrolled its first patient on June 17. The re-activated MERMAIDS-ARI study has also commenced enrolment and 66 patients have been included so far.
A survey to assess perceptions and preparedness of European healthcare workers for COVID-19 is also part of WP3. This health care worker survey has been sent to hospitals in the COMBACTE network and the study team has already received responses from over 1500 health care workers. If you are also interested in participating, you can click here.

ABOUT RECOVER

RECOVER (Rapid European COVID-19 Emergency Research response) is funded by the European Union to respond to the SARS-CoV-2 pandemic and originates from PREPARE (Platform for European Preparedness Against (Re-) emerging Epidemics). It is positioned as PREPARE’s research response plan addressing the most urgent questions for patient and public health and will run for approximately two years (2020-2022). The results of all RECOVER activities (clinical studies in primary and hospital care; epidemiological studies and modelling; and clinical biological studies) will immediately inform the European response to COVID-19.  It will also further strengthen Europe’s clinical research preparedness and inform future research response efforts to further strengthen Europe’s preparedness to future emerging infectious disease outbreaks.

COMBATTING THE COVID-19 PANDEMIC

COMBACTE’s extensive, highly capable clinical and laboratory network is ensuring rapid participation of experienced hospital sites in COVID-19-focused clinical trials. Together with 10 international partners, COMBACTE is part of the RECOVER consortium, putting forward its network to support the clinical trials involved.

Find out what other COVID-19 related activities COMBACTE is involved in. Read more